Galera Therapeutics reports statistically significant results in a 223-patient phase IIb trial of GC4419 for oral mucositis in head and neck cancer

FDA approves Rybrevant Faspro as dual-targeted therapy for advanced head and neck cancer

FDA granted accelerated approval for Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) (subcutaneous injection, 160 mg/2,000 units per mL) as a single agent for the treatment of adults with recurrent or metastatic head and neck squamous cell carcinoma whose disease has progressed on or after platinum‑based chemotherapy and an anti‑PD‑(L)1 antibody.

November 06, 2026

Vol.52 No.41

Clinical Roundup

Rybrevant Faspro combination demonstrates 77% ORR in first-line treatment of advanced head and neck cancer, phase II study finds

First-line subcutaneous Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) plus a PD-1 inhibitor and fixed-duration carboplatin chemotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma showeddeep and durable responses, according to the results from Cohort 5 of the phase Ib/II OrigAMI-4 study.

October 30, 2026

Vol.52 No.40

Clinical Roundup

Earlier survivorship care linked to lower risk of head and neck cancer recurrence and death

Beginning survivorship care for head and neck cancer patients earlier is linked to better survival and lower recurrence, according to the findings of a study led by researchers at the University of Pittsburgh.

October 30, 2026

Vol.52 No.40

Clinical Roundup

Johns Hopkins investigators identify a metabolic weak point in exhausted immune cells in head and neck cancer

Immune cells can reach head and neck tumors, but once there, many stop functioning. This helps explain why immunotherapy with immune checkpoint inhibitors—which have transformed treatment for some cancers—benefit only 17% to 23% of patients with head and neck squamous cell carcinoma.

October 02, 2026

Vol.52 No.36

Clinical Roundup

Rybrevant Faspro + immunotherapy shows strong clinical benefit for recurrent or metastatic head-and-neck cancer

Data from the phase Ib/II OrigAMI-4 study found that first-line treatment with investigational subcutaneous amivantamab and hyaluronidase-lpuj in combination with a PD-1 inhibitor delivered clinically meaningful and durable antitumor activity in patients with head and neck squamous cell carcinoma that is recurrent or metastatic, PD-L1-positive, and HPV-unrelated.

February 27, 2026

Vol.52 No.08

Drugs & Targets

FDA grants Breakthrough Therapy designation to Rybrevant Faspro in advanced head-and-neck cancer

FDA granted Breakthrough Therapy designation for subcutaneous amivantamab and hyaluronidase-lpuj as a monotherapy for the treatment of adults with head-and-neck squamous cell carcinoma that is recurrent or metastatic and human papillomavirus-unrelated after disease progression on or after platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor.

February 20, 2026

Vol.52 No.07

Galera Therapeutics reports statistically significant results in a 223-patient phase IIb trial of GC4419 for oral mucositis in head and neck cancer

YOU MAY BE INTERESTED IN

FDA approves Rybrevant Faspro as dual-targeted therapy for advanced head and neck cancer

Rybrevant Faspro combination demonstrates 77% ORR in first-line treatment of advanced head and neck cancer, phase II study finds

Earlier survivorship care linked to lower risk of head and neck cancer recurrence and death

Johns Hopkins investigators identify a metabolic weak point in exhausted immune cells in head and neck cancer

Rybrevant Faspro + immunotherapy shows strong clinical benefit for recurrent or metastatic head-and-neck cancer

FDA grants Breakthrough Therapy designation to Rybrevant Faspro in advanced head-and-neck cancer

Renew today!

Subscriber content

Never miss an issue!

Login